<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4258">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03051490</url>
  </required_header>
  <id_info>
    <org_study_id>AN-EPI3333</org_study_id>
    <nct_id>NCT03051490</nct_id>
  </id_info>
  <brief_title>RESULT: Reliable, Emergent Solution Using Liprotamase Treatment</brief_title>
  <official_title>A Phase 3, Randomized, Open-Label, Assessor-Blind, Non-Inferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anthera Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anthera Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liprotamase powder is a non-porcine, soluble and stable mixture of biotechnology-derived
      lipase, protease, and amylase digestive enzymes. The purpose of the present study is to to
      evaluate the non-inferiority of liprotamase compared with porcine-derived,
      enterically-coated pancreatic enzyme replacement therapy (PERT). The primary efficacy
      endpoint of the study will be comparative efficacy measured as the change from baseline in
      the coefficient of fat absorption (CFA) in Cystic Fibrosis patients with exocrine pancreatic
      insufficiency (EPI).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2017</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
    <masking_description>unblinded to treatment randomization; blinded to primary efficacy variable</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Coefficient of Fat Absorption (CFA)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Non-inferiority of Liprotamase to approved porcine PERT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coefficient of Nitrogen Absorption (CNA)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Non-inferiority of Liprotamase to approved porcine PERT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety, as measured by number of participants with adverse events or laboratory abnormalities</measure>
    <time_frame>6 months</time_frame>
    <description>Change from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Exocrine Pancreatic Insufficiency</condition>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Liprotamase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individually-optimized dose to be administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>porcine PERT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individually-optimized dose to be administered orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liprotamase</intervention_name>
    <description>oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement</description>
    <arm_group_label>Liprotamase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>porcine PERT</intervention_name>
    <description>oral, enterically-coated, pig-derived, pancreatic enzyme replacement</description>
    <arm_group_label>porcine PERT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Cystic Fibrosis based on presentation, genotype and/or sweat chloride

          -  Fecal elastase &lt;100 mcg/g stool

          -  Good disease control with porcine PERT prior to enrollment

          -  Good nutritional status

        Exclusion Criteria:

          -  History or diagnosis of fibrosing colonopathy

          -  Distal intestinal obstruction syndrome in 6 months prior to screening

          -  Receiving enteral tube feedings

          -  Chronic diarrheal illness unrelated to pancreatic insufficiency

          -  Liver abnormalities, or liver or lung transplant, or significant bowel resection

          -  Forced expiratory volume in 1 second (FEV1) &lt;30%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monica Gangal</last_name>
    <role>Study Director</role>
    <affiliation>Anthera Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Monica Gangal</last_name>
    <email>mgangal@anthera.com</email>
  </overall_contact>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 9, 2017</lastchanged_date>
  <firstreceived_date>February 9, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
